PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016
- PMID: 28144253
- PMCID: PMC5206369
- DOI: 10.5114/aoms.2017.64712
PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016
Conflict of interest statement
Prof. Maciej Banach: lectures: Abbott//Mylan, Abbott Vascular, Actavis, Amgen, KRKA, MSD, Sanofi-Aventis; consultations: Abbott Vascular, Amgen, Daichii Sankyo, Esperion, MSD, Resverlogix, Sanofi-Aventis; Prof. Piotr Jankowski: lectures: Amgen, KRKA, MSD, Sanofi-Aventis; consultations: Amgen, MSD, Sanofi-Aventis; Prof. Jacek Jóźwiak: lectures: Valeant, Beoehringer Ingelheim, Śląskie Laboratoria Analityczne; consultations: Valeant, Bayer, Bioton, Beoehringer Ingelheim, Śląskie Laboratoria Analityczne; Prof. Barbara Cybulska: lectures: Amgen, Sanofi, consultations: MSD, Amgen, Sanofi; Prof. Adam Windak: lectures: MSD, Sanofi-Aventis; consultations: MSD, Sanofi Aventis, Polpharma, Merck; Prof. Tomasz Guzik: lectures: Abbott, G-Pharma, Servier (France); Srteering committee/consultations: Novartis, Sanofi-Aventis, Bayer, ALK-Abello; Prof. Artur Mamcarz: lectures: Abbott//Mylan, Actavis, Amgen, Apotex, Astra-Zeneca, Gedeon Richter, MSD, Polpharma, Sandoz, Sanofi-Aventis, Valeant; consultations: MSD, Polpharma, Valeant; Prof. Marlena Broncel: lectures, articles for: MSD, Sanofi, Amgen, Pfizer, Fournier, Bioton, Polpharma; Prof. Tomasz Tomasik: cooperation: Pfizer and Valeant.
Figures
References
-
- Zdrojewski T, Solnica B, Cybulska B, et al. Prevalence of lipid abnormalities in Poland. The NATPOL 2011 survey. Kardiol Pol. 2016;74:213–23. - PubMed
-
- Rynkiewicz A, Cybulska B, Banach M, et al. Management of familial heterozygous hypercholesterolemia: Position Paper of the Polish Lipid Expert Forum. J Clin Lipidol. 2013;7:217–21. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources